Metastasis-directed therapy is an evolving treatment modality for patients with oligometastatic prostate cancer.
Although the microenvironment of the adrenal glands is enriched in androgen precursors, isolated adrenal metastases are rare.
The application of stereotactic ablative radiotherapy (SBRT) to oligometastatic adrenal lesions has been limited due to toxicity concerns.
